MT-200605

Primary Objective: To evaluate the efficacy of MT200605 in patients with acute ischemic stroke (AIS) by the proportion of subjects achieving target mRS scores on day 90 after treatment. Secondary Objectives: To evaluate the efficacy of MT200605 in patients with AIS by the change from baseline in NIHSS scores within 14 days after treatment; to evaluate the efficacy of MT200605 in patients with AIS by achieving target mRS scores within 90 days after treatment; to evaluate the safety of MT200605 in patients with acute ischemic stroke; to evaluate the improvement of MT200605 in activities of daily living by the proportion of subjects achieving Barthel Index (BI) scores ≥95 on days 30 and 90 after treatment; to evaluate the improvement of MT200605 in quality of life by EQ-5D results on days 30 and 90 after treatment; and to evaluate the pharmacokinetic characteristics of MT200605 in patients with AIS.